NCT05270863 - Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

March 17, 2023

Study Completion Date

April 10, 2023

Conditions

Presbyopia

Interventions

DRUG

BRIMOCHOL™ PF

A single drop in each eye at a visit.

DRUG

Carbachol PF

A single drop in each eye at a visit.

DRUG

Brimonidine tartrate

A single drop in each eye at a visit.

Trial Locations (15)

30076

Visus Therapeutics Investigative Site, Roswell

30260

Visus Therapeutics Investigative Site, Morrow

32204

Visus Therapeutics Investigative Site, Jacksonville

38119

Visus Therapeutics Investigative Site, Memphis

64133

Visus Therapeutics Investigative Site, Kansas City

64154

Visus Therapeutics Investigative Site, Kansas City

66204

Visus Therapeutics Investigative Site, Shawnee Mission

66762

Visus Therapeutics Investigative Site, Pittsburgh

77027

Visus Therapeutics Investigative Site, Memphis

Visus Therapeutics Investigative Site, Houston

78229

Visus Therapeutics Investigative Site, San Antonio

78613

Visus Therapeutics Investigative Site, Cedar Park

84403

Visus Therapeutics Investigative Site, Ogden

91204

Visus Therapeutics Investigative Site, Glendale

95670

Visus Therapeutics Investigative Site, Rancho Cordova